Log in
OTCMKTS:EPRSQ

EPIRUS Biopharmaceuticals Stock Forecast, Price & News

$0.0080
0.00 (0.00 %)
(As of 11/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range N/A
52-Week Range
$0.00
Now: $0.01
$0.01
Volume126,661 shs
Average Volume59,888 shs
Market Capitalization$195,040.00
P/E RatioN/A
Dividend YieldN/A
Beta5.01
EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:EPRSQ
Previous SymbolNASDAQ:EPRS
CUSIPN/A
Phone617-600-3497
Employees73

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$195,040.00
Next Earnings DateN/A
OptionableNot Optionable
$0.0080
0.00 (0.00 %)
(As of 11/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EPRSQ News and Ratings via Email

Sign-up to receive the latest news and ratings for EPRSQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Frequently Asked Questions

How has EPIRUS Biopharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

EPIRUS Biopharmaceuticals' stock was trading at $0.0012 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EPRSQ stock has increased by 566.7% and is now trading at $0.0080.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than EPIRUS Biopharmaceuticals?

Wall Street analysts have given EPIRUS Biopharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but EPIRUS Biopharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were EPIRUS Biopharmaceuticals' earnings last quarter?

EPIRUS Biopharmaceuticals, Inc. (OTCMKTS:EPRSQ) issued its earnings results on Wednesday, August, 20th. The biopharmaceutical company reported ($1.52) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.20) by $0.32.
View EPIRUS Biopharmaceuticals' earnings history
.

Are investors shorting EPIRUS Biopharmaceuticals?

EPIRUS Biopharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 76,800 shares, an increase of 64.1% from the October 31st total of 46,800 shares. Based on an average trading volume of 121,500 shares, the short-interest ratio is presently 0.6 days.
View EPIRUS Biopharmaceuticals' Short Interest
.

Who are some of EPIRUS Biopharmaceuticals' key competitors?

Who are EPIRUS Biopharmaceuticals' key executives?

EPIRUS Biopharmaceuticals' management team includes the following people:
  • Mr. Jeff Kagy, VP of HR & Admin.
  • Jason Yap, Head of Global Regulatory Affairs and Sr. Director
  • Dr. Louis Boon, Head of CLG, Bioassay & Process Devel.
  • Emile Van Corven Ph.D., Head of Analytical Devel. and Downstream PD
  • Dr. Bram Bout Ph.D., Head of Epirus (Netherlands) B.V.

What is EPIRUS Biopharmaceuticals' stock symbol?

EPIRUS Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ."

How do I buy shares of EPIRUS Biopharmaceuticals?

Shares of EPRSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is EPIRUS Biopharmaceuticals' stock price today?

One share of EPRSQ stock can currently be purchased for approximately $0.01.

How big of a company is EPIRUS Biopharmaceuticals?

EPIRUS Biopharmaceuticals has a market capitalization of $195,040.00. EPIRUS Biopharmaceuticals employs 73 workers across the globe.

What is EPIRUS Biopharmaceuticals' official website?

The official website for EPIRUS Biopharmaceuticals is www.epirusbiopharma.com.

How can I contact EPIRUS Biopharmaceuticals?

EPIRUS Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The biopharmaceutical company can be reached via phone at 617-600-3497 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.